Scientists have conducted a study that looks at how traditional initial disease modifying treatment (DMT) choices, including dimethyl fumarate, fingolimod, or natalizumab compare with rituximab in relapsing remitting multiple sclerosis (RRMS) in terms of drug discontinuation and clinical efficacy…Read more - http://www.ms-uk.org/rituximab-superior ... tudy-finds
